Osimertinib effective in EGFR T790M-positive lung cancer

Patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC) given osimertinib had longer progression-free survival (PFS) and were more likely to respond to treatment than those given platinum plus pemetrexed after first-line EGFR tyrosine kinase inhibitor (TKI) therapy, according to trial...

Full description

Bibliographic Details

Published in:	The lancet oncology 2017-01, Vol.18 (1), p.e9-e9
Main Author:	Mayor, Susan
Format:	Article
Language:	eng
Subjects:	Acrylamides Aniline Compounds Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Clinical Trials, Phase III as Topic Disease Progression Disease-Free Survival Drug Resistance, Neoplasm - genetics ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Hematology, Oncology and Palliative Medicine Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Lung Neoplasms - mortality Mutation Piperazines - adverse effects Piperazines - therapeutic use Precision Medicine Prescription drugs Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Randomized Controlled Trials as Topic Time Factors Treatment Outcome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!